Treatment tips

Infusion goes better if patients and caregivers plan ahead. Here are some tips to help ensure the smoothest possible infusion day.

Scheduling

Between the actual infusion and the travel time, infusions can take up most of a day. To make it easier on your work or school schedule, you can try these ideas:

  • Plan with your teacher or boss to do a half‐day on your infusion day
  • Ask for work you can do during the infusion so you don’t miss out
  • Talk to your infusion center to see if weekend or evening appointments are available

Also, keep in mind that lots of people have scheduling conflicts from jobs, childcare, and other responsibilities. You’re not the only one. Most teachers or bosses are used to working with scheduling requests.

Preparing

You’ll need to rest for about 4 hours during the infusion. So plan something fun or useful to do each week. Here are some ideas:

  • Call friends you haven’t talked to in a while
  • Draw
  • Do homework
  • Read
  • Play a video game
  • Learn a language on DVD
  • Watch your favorite TV shows on DVD
  • Write in a journal or blog

Stay with your treatment

Every infusion helps you get rid of more GAG. On the other hand, every time you miss an appointment, GAG builds up. So it is important to go to every appointment. If you miss one for some reason, schedule the next one promptly.

Learn more about the benefits of consistent NAGLAZYME therapy

The discomfort of IV injections can make you anxious. Luckily, there are several ways to ease or prevent needle pain.
Next Page

Important Safety Information

Indication

NAGLAZYME® (galsulfase) is indicated for patients with Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy Syndrome). NAGLAZYME has been shown to improve walking and stair-climbing capacity.

Important Safety Information

Severe and life-threatening allergic reactions can occur during NAGLAZYME (galsulfase) infusions and up to 24 hours after infusion. Typical signs of an allergic reaction include shock, difficulty breathing, wheezing, swelling of the throat, and low blood pressure. If a severe allergic reaction occurs during infusion, the infusion should be stopped immediately and you should receive medical attention. Contact your doctor or get medical help right away if you develop any severe symptoms after infusion.

In clinical trials, most patients developed antibodies to NAGLAZYME treatment. There was no clear relationship between antibody formation and the safety or effectiveness of NAGLAZYME.

Serious and severe infusion reactions are associated with NAGLAZYME, including hives, chest pain, rash, abdominal pain, difficulty breathing, swelling, fever, and eye irritation. You should receive medication such as antihistamines before NAGLAZYME infusions to reduce the risk of infusion reactions. If an infusion reaction occurs, the infusion should be slowed or stopped and you may be given additional medication.

The most common side effects of NAGLAZYME seen in clinical trials were rash, pain, hives, fever, itching, chills, headache, nausea, vomiting, abdominal pain and difficulty breathing. The most common side effects requiring medical attention are infusion-related effects.

These are not all of the possible side effects with NAGLAZYME. Talk to your doctor if you have any symptoms that bother you or that do not go away.

NAGLAZYME is a prescription medicine. Before treatment with NAGLAZYME, it is important to discuss your medical history with your doctor. Tell your doctor if you are taking any medication and if you are allergic to any medicines. Your doctor will decide if NAGLAZYME is right for you. If you have questions or would like more information about NAGLAZYME, contact your doctor.

Spinal cord damage may occur due to the natural MPS VI disease process. Signs of spinal cord injury include back pain, loss of bladder and bowel control, numbness, and paralysis. Contact your doctor immediately if you develop any of these symptoms.

To report SUSPECTED ADVERSE REACTIONS contact BioMarin Pharmaceutical Inc. at 1-866-906-6100, or FDA at 1-800-FDA-1088 or go to www.fda.gov/medwatch.

Please see full Prescribing Information.